FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

仅供研究使用。 完整免责声明 →

肽库

AHK-Cu

Ala-His-Lys-Cu / Copper Peptide AHK

Recovery & Repair

AHK-Cu (Copper Tripeptide Ala-His-Lys-Cu) is a copper-binding tripeptide variant consisting of alanine-histidine-lysine complexed with a copper(II) ion, studied for its potential role in hair growth stimulation and skin rejuvenation. It is structurally related to the more extensively studied GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) but with alanine substituted for glycine at the first position, potentially altering its receptor interactions and biological activity profile. Research applications focus primarily on dermal papilla cell stimulation, wound healing, and cosmetic anti-aging formulations.

作用机制

Synthetic copper-binding tripeptide analog of GHK-Cu with alanine substituted for glycine. Stimulates collagen synthesis and dermal fibroblast proliferation. May offer enhanced stability over GHK-Cu while maintaining copper-dependent tissue remodeling activity.

研究协议

仅供研究使用,非医疗建议。

Research protocols mirror GHK-Cu. Topical: 1-2% concentration. Injectable protocols not well-established. Primarily studied in cosmetic formulations.

研究笔记

Clinical Research Status

AHK-Cu has significantly less published clinical research compared to its well-studied relative GHK-Cu, with most available data coming from in vitro cell culture studies and cosmetic ingredient characterization rather than formal clinical trials. Patent literature and cosmetic industry research reports suggest efficacy in hair follicle stimulation, but independent peer-reviewed clinical validation remains limited. It is available as a cosmetic ingredient and in topical hair growth formulations, but has not been evaluated by the FDA for any medical indication.

Key Published Findings

In vitro studies on human dermal papilla cells demonstrate that AHK-Cu stimulates proliferation and increases production of vascular endothelial growth factor (VEGF) and other growth factors associated with hair follicle angiogenesis. Comparative studies suggest AHK-Cu may have superior hair growth stimulation activity compared to GHK-Cu in certain cell culture models, possibly due to different binding dynamics at the cellular level. The copper ion is essential for activity, participating in extracellular matrix remodeling through lysyl oxidase activation and superoxide dismutase function.

Safety Profile

Copper peptides generally have an excellent topical safety profile, with AHK-Cu showing no significant irritation or sensitization in available patch testing data. Systemic copper toxicity is not a concern at concentrations used in topical formulations (typically 0.001-0.1%). As with all copper peptides, high concentrations may produce a blue-green discoloration of skin or products, and interactions with ascorbic acid (vitamin C) can cause oxidative degradation of both compounds when co-formulated.

Comparison to Related Compounds

GHK-Cu is the most extensively studied copper peptide with over 100 published papers documenting wound healing, anti-inflammatory, and anti-aging effects, while AHK-Cu has a much smaller research base. The alanine substitution in AHK-Cu may provide different tissue specificity or potency for hair follicle applications compared to GHK-Cu's broader tissue effects. Both copper peptides differ fundamentally from minoxidil (a potassium channel opener) and finasteride (a 5-alpha reductase inhibitor), working through growth factor and extracellular matrix pathways rather than vascular or hormonal mechanisms.

Community Observations

Hair loss communities have shown growing interest in AHK-Cu as an addition to topical hair growth regimens, often combined with GHK-Cu, minoxidil, and microneedling protocols. Users report that results are gradual and modest, typically requiring 3-6 months of consistent application to assess efficacy. The peptide is available from specialized cosmetic ingredient suppliers and is increasingly appearing in commercial hair growth serums, though concentration standardization varies significantly between products.

半衰期

~30-60 minutes

复溶

Bacteriostatic water (BAC)

存储

冻干

Refrigerate 2-8C up to 12 months.

复溶后

Refrigerate 2-8C. Use within 14 days.

美国法律状态

Cosmetic/research ingredient

又称作

Ala-His-Lys-CuCopper Peptide AHK

常见问题

什么是 AHK-Cu?

AHK-Cu (Copper Tripeptide Ala-His-Lys-Cu) is a copper-binding tripeptide variant consisting of alanine-histidine-lysine complexed with a copper(II) ion, studied for its potential role in hair growth stimulation and skin rejuvenation. It is structurally related to the more extensively studied GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) but with alanine substituted for glycine at the first position, potentially altering its receptor interactions and biological activity profile. Research applications focus primarily on dermal papilla cell stimulation, wound healing, and cosmetic anti-aging formulations.

AHK-Cu 如何起作用?

Synthetic copper-binding tripeptide analog of GHK-Cu with alanine substituted for glycine. Stimulates collagen synthesis and dermal fibroblast proliferation. May offer enhanced stability over GHK-Cu while maintaining copper-dependent tissue remodeling activity.

AHK-Cu 在美国的监管状态是什么?

Cosmetic/research ingredient

AHK-Cu 的半衰期是多少?

~30-60 minutes

AHK-Cu 还有哪些名称?

Ala-His-Lys-Cu, Copper Peptide AHK

Peptide Contacts仅提供基于研究的摘要,仅供信息参考。我们不托管、分发或支持供应商文档。所有证书分析、GMP证书和供应商通信必须由买家直接请求并验证。本平台上任何内容均不构成法律、医疗或专业建议。用户在购买任何研究化学品之前应自行核实供应商资质,并确保遵守所有适用的当地、州及联邦法律法规,承担全部法律责任。

阅读完整免责声明